Overview

Efficacy and Safety of Tazbentetol in ALS Participants

Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
Phase:
PHASE2
Details
Lead Sponsor:
Spinogenix